Complexity of signal transduction mediated by ErbB2: Clues to the potential of receptor-targeted cancer therapy

Pathology and Oncology Research

Volumn 5, Issue 4, 1999, Pages 255-271

  Nagy, Péter ^a,b,c   Jenei, Attila ^a,c   Damjanovich, Sándor ^a   Jovin, Thomas M ^c   Szôlôsi, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Breast cancer; ErbB proteins; ErbB2; Herceptin; Heteroassociation; Homoassociation

Indexed keywords

PROTEIN TYROSINE KINASE;

BREAST CANCER; CANCER SURVIVAL; NONHUMAN; ONCOGENE NEU; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033367737     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0255     Document Type: Article

References (160)

1. Ahmad I, Longenecker M, Samuel J. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53:1993;1484-1488.
2. Alimandi M, Romano A, Curia M C. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 10:1995;1813-1821.
3. Allred D C, Clark G M, Molina R. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 23:1992;974-979.
4. Allred D C, O'Connell P, Fuqua S A. Biomarkers in early breast neoplasia. J Cell Biochem Suppl. 17:1993;125-131.
5. Andrulis I L, Bull S B, Blackstein M E. neu/erbB-2 ampli-fication identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 16:1998;1340-1349.
6. Bacus S S, Gudkov A V, Zelnick C R. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res. 53:1993;5251-5261.
7. Bacus S S, Huberman E, Chin D. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 3:1992;401-411.
8. Bacus S S, Stancovski I, Huberman E. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 52:1992;2580-2589.
9. Bacus S S, Yarden Y, Oren M. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene. 12:1996;2535-2547.
10. Bargmann C I, Weinberg R A. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA. 85:1988;5394-5398.
11. Barnes D M. c-erbB-2 amplification in mammary carcinoma. J.Cell Biochem Suppl. 17:1993;132-138.
12. Baselga J, Norton L, Albanell J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
13. Baselga J, Seidman A D, Rosen P P. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology Huntingt. 11:1997;43-48.
14. Baselga J, Tripathy D, Mendelsohn J. Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu- overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
15. Baulida J, Kraus M H, Alimandi M. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 271:1996;5251-5257.
16. Beerli R R, Hynes N E. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem. 271:1996;6071-6076.
17. Benz C C, Scott G K, Sarup J C. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 24:1993;85-95.
18. Berns E M, Foekens J A, van Staveren I L. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 159:1995;11-18.
19. Bianco A R, De Laurentiis M, Carlomagno C. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifene efficacy. Proc Am Soc Clin Oncol. 17:1998;97.
20. Bourguignon L Y, Zhu H, Chu A. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem. 272:1997;27913-27918.
21. Brower S T, Ahmed S, Tartter P I. Prognostic variables in invasive breast cancer: contribution of comedo versus non-comedo in situ component. Ann Surg Oncol. 2:1995;440-444.
22. Burke C L, Stern D F. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol. 18:1998;5371-5379.
23. Campiglio M, Tagliabue E, Srinivas U. Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells. J Cell Biochem. 55:1994;409-418.
24. Canman C E, Gilmer T M, Coutts S B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9:1995;600-611.
25. Carraway K L, Sliwkowski M X, Akita R. The erbB3 gene product is a receptor for heregulin. J Biol Chem. 269:1994;14303-14306.
26. Chakrabarti A, Matkó J, Rahman N A. Self-association of class I major histocompatibility complex molecules in liposome and cell surface membranes. Biochemistry. 31:1992;7182-7189.
27. Chamberlin S G, Davies D E. A unified model of c-erbB receptor homo- and heterodimerisation. Biochim Biophys Acta. 1384:1998;223-232.
28. Chen L I, Webster M K, Meyer A N. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. J Cell Biol. 137:1997;619-631.
29. Cohen B D, Kiener P A, Green J M. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem. 271:1996;30897-30903.
30. Crovello C S, Lai C, Cantley L C. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. J Biol Chem. 273:1998;26954-26961.
31. D'Souza B, Berdichevsky F, Kyprianou N. Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene. 8:1993;1797-1806.
32. D'Souza B, Taylor Papadimitriou J. Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc Natl Acad Sci USA. 91:1994;7202-7206.
33. Dalifard I, Daver A, Goussard J. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification. Int J Mol Med. 1:1998;855-861.
34. Daly J M, Jannot C B, Beerli R R. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res. 57:1997;3804-3811.
35. Damjanovich S, Vereb G, Schaper A. Structural hierarchy in the clustering of HLA class I molecules in the plasma membrane of human lymphoblastoid cells. Proc Natl Acad Sci USA. 92:1995;1122-1126.
36. De Corte V, De Potter C, Vandenberghe D. A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells. J Cell Sci. 107:1994;405-416.
37. De Potter C R, Quatacker J. The p185erbB2 protein is localized on cell organelles involved in cell motility. Clin Exp Metastasis. 11:1993;453-461.
38. Di Fiore P P, Segatto O, Lonardo F. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol. 10:1990;2749-2756.
39. Discafani C M, Carroll M L, Floyd M B. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-qui-nazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol. 57:1999;917-925.
40. Disis M L, Grabstein K H. HER2/neu peptide vaccines elicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. Proc Am Soc Clin Oncol. 17:1998;97.
41. Drebin J A, Link V C, Stern D F. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 41:1985;697-706.
42. Dykins R, Corbett I P, Henry J A. Long-term survival in breast cancer related to overexpression of the c-erbB-2 onco-protein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol. 163:1991;105-110.
43. Edidin M. Lipid microdomains in cell surface membranes. Curr Opin Struct Biol. 7:1997;528-532.
44. Engelman J A, Lee R J, Karnezis A. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem. 273:1998;20448-20455.
45. Ethier S P, Langton B C, Dilts C A. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha. Mol Carcinog. 15:1996;134-143.
46. Falcioni R, Antonini A, Nistico P. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res. 236:1997;76-85.
47. Fan Z, Baselga J, Masui H. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53:1993;4637-4642.
48. Fendly B M, Winget M, Hudziak R M. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50:1990;1550-1558.
49. French A R, Tadaki D K, Niyogi S K. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem. 270:1995;4334-4340.
50. Gadella T W, Jovin T M. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J Cell Biol. 129:1995;1543-1558.
51. Gamett D C, Pearson G, Cerione R A. Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem. 272:1997;12052-12056.
52. Gassmann M, Casagranda F, Orioli D. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 378:1995;390-394.
53. Giani C, Casalini P, Pupa S M. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene. 17:1998;425-432.
54. Graus Porta D, Beerli R R, Daly J M. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
55. Graus Porta D, Beerli R R, Hynes N E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol. 15:1995;1182-1191.
56. Gronowski A M, Bertics P J. Modulation of epidermal growth factor receptor interaction with the detergent-insoluble cytoskeleton and its effects on receptor tyrosine kinase activity. Endocrinology. 136:1995;2198-2205.
57. Grunt T W, Saceda M, Martin M B. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer. 63:1995;560-567.
58. Gullick W J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 47:1991;87-98.
59. Gusterson B A, Gelber R D, Goldhirsch A. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 10:1992;1049-1056.
60. Haerslev T, Jacobsen G K. c-erbB-2 oncoprotein is not an independent prognostic parameter in primary breast carcinoma. An immunohistochemical study. APMIS. 102:1994;612-622.
61. Harbeck N, Dettmar P, Thomssen C. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res. 18:1998;2187-2197.
62. Harder T, Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol. 9:1997;534-542.
63. Hartmann F, Horak E M, Cho C. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer. 70:1997;221-229.
64. Heldin C H. Dimerization of cell surface receptors in signal transduction. Cell. 80:1995;213-223.
65. Hellyer N J, Cheng K, Koland J G. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J. 333:1998;757-763.
66. Houston S J, Plunkett T A, Barnes D M. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 79:1999;1220-1226.
67. Hudziak R M, Lewis G D, Winget M. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 9:1989;1165-1172.
68. Hwang J, Gheber L A, Margolis L. Domains in cell plasma membranes investigated by near-field scanning optical microscopy. Biophys J. 74:1998;2184-2190.
69. Hynes N E, Stern D F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1198:1994;165-184.
70. Kallioniemi O P, Holli K, Visakorpi T. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 49:1991;650-655.
71. Kameda T, Yasui W, Yoshida K. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 50:1990;8002-8009.
72. Karunagaran D, Tzahar E, Beerli R R. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15:1996;254-264.
73. Kenworthy A K, Edidin M. Distribution of a glycosylphosphatidylinositol-anchored protein at the apical surface of MDCK cells. J Cell Biol. 142:1998;69-84.
74. Kim H H, Vijapurkar U, Hellyer N J. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J. 334:1998;189-195.
75. Kirpotin D, Park J W, Hong K. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:1997;66-75.
76. Klapper L N, Vaisman N, Hurwitz E. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks cross-talk with growth factor receptors. Oncogene. 14:1997;2099-2109.
77. Knowlden J M, Gee J M, Seery L. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene. 17:1998;1949-1957.
78. Kraus M H, Issing W, Miki T. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA. 86:1989;9193-9197.
79. Kuan C T, Pastan I. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. Biochemistry. 35:1996;2872-2877.
80. Lee K F, Simon H, Chen H. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;394-398.
81. Lemmon M A, Bu Z, Ladbury J E. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16:1997;281-294.
82. Lemmon M A, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 19:1994;459-463.
83. Levkowitz G, Klapper L N, Tzahar E. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 12:1996;1117-1125.
84. Lewis G D, Figari I, Fendly B. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 37:1993;255-263.
85. Li W, Park J W, Nuijens A. Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. Oncogene. 12:1996;2473-2477.
86. Lipponen H J, Aaltomaa S, Syrjanen S. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res. 13:1993;1147-1152.
87. Liu X, Pogo B G. Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 6:1996;9-16.
88. Liu Y, Martindale J L, Gorospe M. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 56:1996;31-35.
89. Lofts F J, Hurst H C, Sternberg M J. Specific short trans-membrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene. 8:1993;2813-2820.
90. Lupu R, Colomer R, Kannan B. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA. 89:1992;2287-2291.
91. Marte B M, Jeschke M, Graus Porta D. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Mol Endocrinol. 9:1995;14-23.
92. McNeil C. Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst. 90:1998;882-883.
93. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 378:1995;386-390.
94. Murali R, Brennan P J, Kieber Emmons T. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. Proc Natl Acad Sci USA. 93:1996;6252-6257.
95. Nagy P, Bene L, Balázs M. EGF-induced redistribution of erbB2 on breast tumor cells: Flow and image cytometric energy transfer measurements. Cytometry. 32:1998;120-131.
96. Nagy P, Jenei A, Kirsch A K. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J Cell Sci. 112:1999;1733-1741.
97. Niemann C, Brinkmann V, Spitzer E. Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol. 143:1998;533-545.
98. Norton L. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol. 26:1999;11-20.
99. Nowak F, Jacquemin Sablon A, Pierre J. Expression of the activated p185erbB2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not confer oncogenicity. Exp Cell Res. 231:1997;251-259.
100. Olayioye M A, Graus Porta D, Beerli R R. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol. 18:1998;5042-5051.
101. Ouyang X, Gulliford T, Huang G. Transforming growth factor-alpha short-circuits downregulation of the epidermal growth factor receptor. J Cell Physiol. 179:1999;52-57.
102. Papahadjopoulos D, Allen T M, Gabizon A. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 88:1991;11460-11464.
103. Park J W, Hong K, Carter P. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA. 92:1995;1327-1331.
104. Pegram M D, Finn R S, Arzoo K. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15:1997;537-547.
105. Pegram M D, Lipton A, Hayes D F. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:1998;2659-2671.
106. Peiper M, Goedegebuure P S, Linehan D C. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol. 27:1997;1115-1123.
107. Petit A M, Rak J, Hung M C. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 151:1997;1523-1530.
108. Pietras R J, Arboleda J, Reese D M. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:1995;2435-2446.
109. Pietras R J, Fendly B M, Chazin V R. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9:1994;1829-1838.
110. Pietras R J, Pegram M D, Finn R S. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 17:1998;2235-2249.
111. Pinkas Kramarski R, Shelly M, Glathe S. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem. 271:1996;19029-19032.
112. Plowman G D, Culouscou J M, Whitney G S. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA. 90:1993;1746-1750.
113. Press M F, Hung G, Godolphin W. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54:1994;2771-2777.
114. Press M F, Pike M C, Chazin V R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:1993;4960-4970.
115. Qian X, Dougall W C, Hellman M E. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene. 9:1994;1507-1514.
116. Qian X, O'Rourke D M, Fei Z. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. J Biol Chem. 274:1999;574-583.
117. Quenel N, Wafflart J, Bonichon F. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 35:1995;283-291.
118. Revillion F, Bonneterre J, Peyrat J P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 34:1998;791-808.
119. Riethmacher D, Sonnenberg Riethmacher E. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 389:1997;725-730.
120. Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 16:1998;413-428.
121. Sarup J C, Johnson R M, King K. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:1991;72-82.
122. Schechter A L, Hung M C, Vaidyanathan L. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science. 229:1985;976-978.
123. Schroeder J A, Lee D C. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ. 9:1998;451-464.
124. Shackney S E, A, Smith C A. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Clin Cancer Res. 4:1998;913-928.
125. Shelly M, Pinkas Kramarski R, Guarino B C. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem. 273:1998;10496-10505.
126. Silletti S, Paku S, Raz A. Tumor cell motility and metastasis. Autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol Oncol Res. 3:1997;230-254.
127. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 387:1997;569-572.
128. Sjogren S, Inganas M, Lindgren A. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 16:1998;462-469.
129. Skarpen E, Johannessen L E, Bjerk K. Endocytosed epidermal growth factor (EGF) receptors contribute to the EGF-mediated growth arrest in A431 cells by inducing a sustained increase in p21/CIP1. Exp Cell Res. 243:1998;161-172.
130. Slamon D J, Clark G M, Wong S G. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
131. Sliwkowski M X, Schaefer G, Akita R W. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem. 269:1994;14661-14665.
132. Soltoff S P, Carraway K L, Prigent S A. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 14:1994;3550-3558.
133. Srinivasan R, Poulsom R, Hurst H C. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol. 185:1998;236-245.
134. Stancovski I, Hurwitz E, Leitner O. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA. 88:1991;8691-8695.
135. Szöllôsi J, Balázs M, Feuerstein B G. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 55:1995;5400-5407.
136. Szöllôsi J, Horejsi V, Bene L. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol. 157:1996;2939-2946.
137. Tagliabue E, Centis F, Campiglio M. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer. 47:1991;933-937.
138. Tan M, Grijalva R, Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 59:1999;1620-1625.
139. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1997;1199-1205.
140. Taylor S L, Platt Higgins A, Rudland P S. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer. 76:1998;459-463.
141. Tetu B, Brisson J. Prognostic significance of HER-2/neu onco-protein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer. 73:1994;2359-2365.
142. Timar J, Trikha M, Szekeres K. Expression and function of the high affinity alphaIIbbeta3 integrin in murine melanoma cells. Clin Exp Metastasis. 16:1998;437-445.
143. Tiwari R K, Borgen P I, Wong G Y. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12:1992;419-425.
144. Tzahar E, Pinkas Kramarski R. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 16:1997;4938-4950.
145. Tzahar E, Waterman H, Chen X. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 16:1996;5276-5287.
146. Vaughn J P, Iglehart J D, Demirdji S. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA. 92:1995;8338-8342.
147. Verbeek B S, Adriaansen Slott S S, Vroom T M. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 425:1998;145-150.
148. Warri A M, Laine A M, Majasuo K E. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer. 49:1991;616-623.
149. Waterman H, Sabanai I, Geiger B. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem. 273:1998;13819-13827.
150. Wiechen K, Zimmer C, Dietel M. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther. 5:1998;45-51.
151. Willsher P C, Pinder S E, Gee J M. C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res. 18:1998;3695-3698.
152. Witters L M, Kumar R, Chinchilli V M. Enhanced antiproliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat. 42:1997;1-5.
153. Worthylake R, Opresko L K, Wiley H S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both erbB-2 and epidermal growth factor receptors. J Biol Chem. 274:1999;8865-8874.
154. Wright C, Cairns J, Cantwell B J. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer. 65:1992;271-274.
155. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene. 18:1999;731-738.
156. Yen L, Nie Z R, You X L. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. Oncogene. 14:1997;1827-1835.
157. Yu D, Liu B, Tan M. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 13:1996;1359-1365.
158. Zafrani B, Leroyer A, Fourquet A. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol. 11:1994;208-214.
159. Zidovetzki R, Johnson D A, Arndt Jovin D J. Rotational mobility of high-affinity epidermal growth factor receptors on the surface of living A431 cells. Biochemistry. 30:1991;6162-6166.
160. Zidovetzki R, Yarden Y, Schlessinger J. Microaggregation of hormone-occupied epidermal growth factor receptors on plasma membrane preparations. EMBO J. 5:1986;247-250.